methyl-CpG binding (MBD) proteins appear to bind differentially methylated domains (DMDs) of DNA, to recruit repression complexes, and to silence the locus. The methyl CpG binding domain of human MBD3 may not directly bind mCpG but does interact with the NuRD/Mi2 components HDAC1 and MTA2. Plays a role in histone deacetylation and nucleosome remodeling. Increased levels have been reported in lung cancer and glioblastomas and may be a therapeutic target. Note: This description may include information from UniProtKB.
Protein type: Gene silencing; Transcription, coactivator/corepressor
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.